EVVIVAX is a spin-off of Takis Biotech, a company developing a number of Innovative Immunotherapies

EVVIVAX is at the forefront of nucleic-acid based therapies, process development, industrial scale production and clinical trial execution

EVVIVAX stems from new, European platform technologies, aims to offer novel therapeutic avenues to pet cancer patients, with the strong translational potential to complement current human Immune-Oncology approaches in the next future.